11 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 17 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 11, Unknown 3, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow cetrorelix: new trials by email Literature Review of cetrorelix trials Research Report on cetrorelix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A GnRH antagonist, MPA - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation | Phase 3 | Not yet recruiting | ShangHai Ji Ai Genetics & IVF Institute | 204 | 2027-06-01 | 2026-11-09 |
| A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) Follitropin alfa/lutropin alfa (MBJ-0011), hMG, Cetrorelix acetate - Infertility | Phase 3 | Recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 266 | 2026-02-05 | 2026-10-29 |
| Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI Dydrogesterone Tablets, Cetrorelix - IVF, PCO | Phase 2 / Phase 3 | Completed | Beni-Suef University | 200 | 2024-01-01 | 2026-04-15 |
| Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes Dydrogesterone, Cetrorelix acetate, Triptorelin - IVF | Phase 3 | Unknown | Beni-Suef University | 387 | 2023-07-15 | 2023-08-02 |
| PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial Dydrogesterone Oral Tablet, Cetrorelix (Cetrotide) - PPOS, GnRH Antagonist | Phase 3 | Completed | Kasr El Aini Hospital | 328 | 2023-01-03 | 2025-03-11 |
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A GnRH antagonist, oral Duphaston - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 400 | 2020-06-10 | 2025-05-31 |
| Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response Progesterone, GnRH Antagonist - IVF, GnRH Antagonist | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 784 | 2020-06-04 | 2023-08-30 |
| Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND) FE 999049 + GnRH agonist (GONAPEPTYL), FE 999049 + GnRH antagonist (CETROTIDE) - Infertility, Female | Phase 3 | Completed | Ferring Pharmaceuticals | 437 | 2019-04-29 | 2024-05-13 |
| Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase cetrotide - Other Complications Associated With Artificial Fertilization | Phase 3 | Completed | Cairo University | 60 | 2015-01-01 | 2016-01-27 |
| Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome Cetrorelix - Infertility | Phase 2 / Phase 3 | Unknown | Benha University | 48 | 2014-10-01 | 2017-03-30 |
| Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) degarelix (long acting GnRH antagonist), cetrorelix 0.25mg - PCOS, OHSS | Phase 3 | Completed | Centre for Endocrinology and Reproductive Medicine, Italy | 80 | 2012-11-01 | 2016-04-27 |
| The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol ghrh antagonist (cetrotide/orgalutran), gnrh agonist (suprefact) - Embryo's Genetic and Chromosomal Quality | Phase 3 | Unknown | European Hospital | 200 | 2012-09-01 | 2012-07-10 |
| GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome GnRH antagonist (Cetrorelix), Placebo (saline solution) - Ovarian Hyperstimulation Syndrome, Effects of Gonadotropin | Phase 3 | Completed | Instituto Valenciano de Infertilidad, IVI VALENCIA | 100 | 2012-04-01 | 2013-09-19 |
| GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer GnRH antagonist (Cetrorelix), Conventional GnRH agonist (Triptorelin) - Infertility, Polycystic Ovary Syndrome | Phase 3 | Completed | Seoul National University Hospital | 43 | 2011-06-01 | 2017-10-10 |
| Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) Cetrorelix acetate, Recombinant Human Choriogonadotropin (r-hCG), Recombinant human follicle stimulating hormone (r-hFSH) - Polycystic Ovarian Syndrome | Phase 3 | Completed | Merck KGaA, Darmstadt, Germany | 136 | 2008-11-01 | 2014-02-13 |
| Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) Cetrorelix Pamoate - Benign Prostatic Hypertrophy | Phase 3 | Completed | AEterna Zentaris | 528 | 2008-03-01 | 2011-04-05 |
| Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo - Benign Prostatic Hypertrophy | Phase 3 | Terminated | AEterna Zentaris | 667 | 2007-03-01 | 2018-08-03 |
Infertility (4) · Polycystic Ovary Syndrome (3) · Prostatic Hyperplasia (2) · Infertility, Female (1) · Ovarian Hyperstimulation Syndrome (1)
ShangHai Ji Ai Genetics & IVF Institute (3) · AEterna Zentaris (2) · Beni-Suef University (2) · Benha University (1) · Cairo University (1) · Centre for Endocrinology and Reproductive Medicine, Italy (1) · European Hospital (1) · Ferring Pharmaceuticals (1) · Instituto Valenciano de Infertilidad, IVI VALENCIA (1) · Kasr El Aini Hospital (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck KGaA, Darmstadt, Germany (1) · Seoul National University Hospital (1)
Egypt (5) · Italy (3) · Canada (2) · China (2) · United States (2) · Austria (1) · Bulgaria (1) · Denmark (1) · France (1) · Germany (1) · Israel (1) · Japan (1) · Netherlands (1) · Norway (1) · South Korea (1)
Ahmed M Maged, MD (1) · Dr. Hebert Lepor, MD (1) · Juan Giles, MD (1) · Marco Sbracia, MD (1) · Young Min Choi, M.D., Ph.D. (1)
PMID 22197127, PMID 29132339, PMID 38272383, PMID 38521533, PMID 38723189, PMID 42819751
2017 (1)